Veritas In Silico

Veritas In Silico Net Margin

The Net Profit Margin of Veritas In Silico (130A.T) as of Oct 27, 2026 is -467.05 %. In the previous year, Net Profit Margin was -121.47 % — a change of 284.48% (lower).

Net Margin

-467.05 %

YoY

284.48%

Last updated:

Net Profit Margin of Veritas In Silico is 2025 -467.05 % . Net Profit Margin of Veritas In Silico was 2024 -121.47 % . It decreases by 284.48% lower compared to the previous year.

Veritas In Silico's net margin stands at -467.1%, down from -426.8% several years earlier.

The Veritas In Silico Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2021
-391.57 JPY
Jan 1, 2022
-79.07 JPY
Jan 1, 2023
9.17 JPY
Jan 1, 2024
-121.47 JPY
Jan 1, 2025
-467.05 JPY
The Veritas In Silico Net Margin history
YEARNet MarginYoY
-467.05 %+284.48%
-121.47 %-1,424.56%
9.17 %-111.60%
-79.07 %-79.81%
-391.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veritas In Silico Stock analysis

What does Veritas In Silico do? Veritas In Silico Inc generates revenue through its ibVIS platform, which provides small molecule drug discovery services targeting mRNA. The company collaborates with pharmaceutical companies on joint drug discovery research to develop mRNA-targeted small molecule drugs. Its primary customers are pharmaceutical companies seeking innovative drug discovery solutions. The business focuses on integrating digital technology, including in silico RNA structural analysis, into the pharmaceutical discovery process. The company's core product, the ibVIS platform, combines in silico RNA structural analysis with drug discovery technology to accelerate the development of small molecule drugs targeting mRNA. This platform is offered as a service to pharmaceutical partners, enabling them to leverage advanced digital tools for more efficient drug discovery. The revenue model is based on contractual agreements with pharmaceutical firms for joint research projects. Veritas In Silico Inc's business model centers on providing specialized technology services to the pharmaceutical industry. The company does not sell physical products but offers its platform as a service for drug discovery. Its target market consists of pharmaceutical companies interested in mRNA-targeted therapies, which represent a growing segment in pharmaceutical research and development. Veritas In Silico is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veritas In Silico stock

Net Profit Margin of Veritas In Silico is -467.05 % in 2025.

Net Profit Margin of Veritas In Silico changed from -121.47 % to -467.05 %, representing a 284.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Veritas In Silico since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Veritas In Silico with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Veritas In Silico

All Key Metrics — Veritas In Silico